IGROV-1/APL resistant cell line shows the typical MDR phenotype : ( 1 ) increased expression of membrane-associated P-glycoprotein , ( 2 ) cross-resistance to drugs like etoposide , doxorubicin , vinblastine , vincristine , taxol , colchicin and the novel anticancer drug Yondelis ( ET-743 ) .
Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression. Aplidin-resistant IGROV-1/APL cells were derived from the human ovarian cancer IGROV-1 cell line by exposing the cells to increasing concentration of Aplidin for eight months, starting from a concentration of 10 nM to a final concentration of 4 microM. IGROV-1/APL cell line possesses five fold relative resistance to Aplidin. IGROV-1/APL resistant cell line shows the typical MDR phenotype : ( 1 ) increased expression of membrane-associated P-glycoprotein , ( 2 ) cross-resistance to drugs like etoposide , doxorubicin , vinblastine , vincristine , taxol , colchicin and the novel anticancer drug Yondelis ( ET-743 ) . The Pgp inhibitor cyclosporin-A restored the sensitivity of IGROV-1/APL cells to Aplidin by increasing the drug intracellular concentration. The resistance to Aplidin was not due to the other proteins, such as LPR-1 and MRP-1, being expressed at the same level in resistant and parental cell line. The finding that cells over-expressing Pgp are resistant to Aplidin was confirmed in CEM/VLB 100 cells, that was found to be 5-fold resistant to Aplidin compared to the CEM parental cell line.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression. Aplidin-resistant IGROV-1/APL cells were derived from the human ovarian cancer IGROV-1 cell line by exposing the cells to increasing concentration of Aplidin for eight months, starting from a concentration of 10 nM to a final concentration of 4 microM. IGROV-1/APL cell line possesses five fold relative resistance to Aplidin. IGROV-1/APL resistant cell line shows the typical MDR phenotype : ( 1 ) increased expression of membrane-associated P-glycoprotein , ( 2 ) cross-resistance to drugs like etoposide , doxorubicin , vinblastine , vincristine , taxol , colchicin and the novel anticancer drug Yondelis ( ET-743 ) . The Pgp inhibitor cyclosporin-A restored the sensitivity of IGROV-1/APL cells to Aplidin by increasing the drug intracellular concentration. The resistance to Aplidin was not due to the other proteins, such as LPR-1 and MRP-1, being expressed at the same level in resistant and parental cell line. The finding that cells over-expressing Pgp are resistant to Aplidin was confirmed in CEM/VLB 100 cells, that was found to be 5-fold resistant to Aplidin compared to the CEM parental cell line.

            ### Response:
            etoposide, doxorubicin, vinblastine, vincristine
            